Sinapsos Podcast | Oncology

E45   |  19 min   |   Latest   |  Publication Link Podcast based on: Philipovskiy, A.; Shurmur, S.; Abid, M.B. Antibody–Drug Conjugates in Contemporary Oncology: A Clinical Perspective on Dose Optimization, Sequencing, and Combination Strategies. Cancers 2026, 18, 2652. https://doi.org/10.3390/cancers18162652 Type: Review  |  Publication date: 17 August 2026 Summary: Antibody–drug conjugates are cancer treatments designed to deliver potent cytotoxic drugs more selectively to tumor cells by linking a tumor-directed antibody to a therapeutic payload. This review examines the structural and biologic features that determine clinical activity, including target selection, linker stability, payload class, drug-to-antibody ratio, tumor penetration, biomarkers, toxicity, and resistance. Particular attention is given to the practical questions emerging as multiple ADCs enter the same malignancies and earlier treatment settings: how to select a biologically efficient dose, how to sequence agents with overlapping targets or payloads, and how to distinguish rational combinations from combinations that merely add toxicity. The next phase of ADC development will require not only improved molecular engineering, but also a more disciplined clinical framework for selecting, dosing, sequencing, and combining these agents. Keywords: antibody–drug conjugates; dose optimization; sequencing; combination strategies; biomarkers; resistance; interstitial lung disease; linker; payload; translational oncology   Disclaimer: This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.  

E44   |  18 min   |   Latest   |  Publication Link Podcast based on: Cano-Uceda, A.; Pareja-García, P.; Sánchez-Rodríguez, E.; Fraguas-Ramos, D.; Martín-Álvarez, L.; Asencio-Vicente, R.; Rivero-de la Villa, A.; Pérez-Pérez, M.d.M.; Obispo-Portero, B.M.; Morales-Ruiz, L.; de Dios-Álvarez, R.; Sanchez-Barroso, L.; De Sousa-De Sousa, L.; Maté-Muñoz, J.L.; García-Fernández, P. Effects of a 6-Week Supervised Multimodal Exercise Program on Cancer-Related Fatigue, Quality of Life and Physical Function During Active Treatment: A Randomized Controlled Trial. Cancers 2026, 18, 947. https://doi.org/10.3390/cancers18060947 Type: Article  |  Publication date: 13 March 2026 Summary: Reduced quality of life, cancer-related fatigue, and functional impairment are common problems during and after cancer treatment. To examine this issue, a randomized clinical trial was conducted with 110 patients with stage I–III cancer. Participants were randomly assigned either to an intervention group, which completed a six-week supervised exercise program, or to a control group that received usual care. The exercise program included cardiorespiratory training, strength exercises, and stretching, with intensity monitored through perceived exertion. Quality of life, fatigue, functional capacity, and muscle strength were assessed. The group that completed the exercise program showed significant and clinically meaningful improvements in fatigue, global quality of life, functional capacity, and muscle strength compared with the control group. Furthermore, a higher percentage of participants in the intervention group achieved improvements considered clinically important. Among symptoms, only insomnia showed a significant reduction. Conclusion: A brief, supervised therapeutic exercise program of moderate to vigorous intensity is safe and effective for improving fatigue, quality of life, and physical function in patients with cancer, and may be suitable for integration into routine oncologic care. Keywords: therapeutic exercise; cancer; quality of life; physical function; fatigue; short-duration intervention   Disclaimer: This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.  

E43   |  15 min   |   Latest   |  Publication Link Podcast based on: Paratore, S.; Russo, A.; Lanzafame, K.; Blanco, G.; Giurato, E.; Bartoloni, G.; D’Asta, M.; Sapienza, M.; Bonanno, G.M.; Vallone, A.; Ettore, G.; Bordonaro, R. Prognostic Stratification of Multiple-Classifier Endometrial Cancers: Cohort Study and Meta-Analysis. Cancers 2026, 18, 929. https://doi.org/10.3390/cancers18060929 Type: Article  |  Publication date: 12 March 2026 Summary: The classification of endometrial cancer has evolved using molecular features, allowing for improved risk assessment and more personalized treatment strategies. However, a small proportion of tumors show more than one relevant molecular alteration, making their classification and clinical management more challenging. This study aimed to characterize molecular and clinicopathological profiles of multiple-classifier endometrial cancers, enhancing our understanding of their biological heterogeneity. In our patient cohort, POLEmut tumors with concurrent MMRd/MSI generally retained the POLE-associated ultramutated profile, while tumors with both MMRd/MSI and p53abn/TP53mut alterations were more often associated with more adverse clinicopathological characteristics compared to MMRd/MSI-only tumors. By integrating our data in a systematic literature review with meta-analysis, we observed that variability in reported incidence is largely driven by differences in testing strategies. These results highlight the limitations of current classification systems and emphasize the importance of more standardized molecular approaches to improve risk stratification and management in endometrial cancer. Keywords: endometrial cancer; molecular profile; clinicopathological features; multiple-classifier; POLE mutated; mismatch repair-deficient; TP53mutated; next generation sequencing   Disclaimer: This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.  

E42   |  20 min   |   Latest   |  Publication Link Podcast based on: Lee, C.; Park, K.; Park, S.; Kim, M.; Hwang, J. Diffuse Leptomeningeal Glioneuronal Tumor: A Systematic Review Highlighting Molecular Heterogeneity and Survival Outcome. Cancers 2026, 18, 912. https://doi.org/10.3390/cancers18060912 Type: Systematic Review  |  Publication date: 11 March 2026 Summary: Diffuse leptomeningeal glioneuronal tumor is a very rare brain tumor that mainly affects children and young adults and often spreads along the brain and spinal cord. Because it is uncommon and difficult to diagnose, treatment strategies vary widely and clinical outcomes remain unpredictable. To address this, we reviewed all published cases reported since this tumor was first defined to summarize clinical features, genetic findings, treatments, and survival outcomes. We found that hydrocephalus and spinal involvement were common, and that surgery was associated with longer survival in selected patients. Genetic alterations affecting tumor growth–related pathways were also frequently observed. This summary of current evidence may help clinicians recognize this tumor earlier and consider appropriate management strategies. Keywords: diffuse leptomeningeal glioneuronal tumor; leptomeningeal dissemination; BRAF fusion; MAPK pathway; pediatric low-grade glioma; molecular heterogeneity; survival analysis   Disclaimer: This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.  

E41   |  22 min   |   Latest   |  Publication Link Podcast based on: Wojnicka, J.; Kiełbus, M.; Mertowska, P.; Mertowski, S.; Grywalska, E.; Sosnowski, P.; Wielgosz, A.; Kozub-Pędrak, A.; Sosnowska-Pasiarska, B.; Klatka, M.; Klatka, J.; Błażewicz, A. Specific Lipidomic Shifts in Chronic Lymphocytic Leukemia at Diagnosis. Cancers 2026, 18, 896. https://doi.org/10.3390/cancers18060896 Type: Article  |  Publication date: 10 March 2026 Summary: Chronic lymphocytic leukemia (CLL) is a common type of adult blood cancer in which cells survive longer than normal, partly due to changes in how they process fats and other molecules for energy. This study examined the blood plasma of newly diagnosed patients who had not yet received treatment to identify unique patterns in lipid molecules. We found that patients with CLL had higher levels of certain fats, including carnitines and specific phospholipids, compared with healthy individuals. By analyzing these lipid changes using predictive bioinformatics tools, we identified that several pathways involved in lipid metabolism are likely disrupted. These findings improve our understanding of how this disease alters the body’s metabolism and could inform future research on biomarkers for earlier disease detection and treatment development. Keywords: chronic lymphocytic leukemia (CLL); metabolic reprogramming; carnitines; ether-linked phospholipids; lipidomics   Disclaimer: This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.